Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

VA launches major trial of THC and CBD for Veterans' nerve pain

NCT ID NCT05351801

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial is testing whether cannabis-based medicines—THC, CBD, or a combination—can safely reduce chronic nerve pain in Veterans. 320 participants will receive one of these treatments or a placebo for six weeks. The goal is to see if these options offer better pain relief than current treatments, which often fall short.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
THC (Syndros), CBD (Epidiolex), and THC+CBD (Nabiximols)
What this could lead to
If successful, this trial could provide evidence that cannabis-based medicines are a safe and effective option for managing chronic neuropathic pain, especially for Veterans.
What could go wrong
This is a mid-stage trial with 320 participants, so results are not definitive. The effects may be modest, and side effects like dizziness or drowsiness are possible. It also focuses on Veterans, so findings may not apply to everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 320 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2023

Expected to finish

May 2029

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a US federal agency other than the NIH.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

21 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Able to provide written consent * Veterans 21 years and older at the date of screening * Meet diagnostic criteria for neuropathic pain as defined by the Neuropathic Pain Special Interest Group of the International Association for the Study of Pain (NeuPSIG) * Meet criteria for persistent, high-impact pain criteria. * Presence of allodynia confirmed by one of the screening dynamic brush tests * women of childbearing potential who agree to abide by contraceptive requirements Exclusion Criteria: * Actively engaged in or planning to enter a program of non-pharmacological invasive intervention for pain at the time of enrollment * Peripheral neuropathy is not a primary source of neuropathic pain * Hypersensitivity to THC, CBD, or THC/CBD * Self-report of cannabis use during screening phase confirmed by positive urine toxicology for THC-COOH as measured and resulted at visit 5 before randomization * Unwilling to refrain from using cannabis or cannabis-based products through the entire duration of the study * Diagnosis of DSM-5 Cannabis Use Disorder in the past 6 months * Current DSM-5 diagnosis of cannabis use disorder, substance use disorder or serious psychiatric disorders * Actual change or intent to change is greater than a 20% change (increase or decrease) in any other medication for pain or non-pharmacological treatment from 4 weeks before the screening appointment until completion of study (i.e., visit 13) * Opioid doses \> 400 mg MME (morphine milligram equivalent) * Women who are pregnant or breastfeeding, or who intend to become pregnant in the 12 weeks from enrollment * Any current unstable or concerning medical condition that would place the patient at increased risk, including hepatic, respiratory, immunological, cardiovascular, endocrine, or renal disease, or in the opinion of the investigator, prevents adherence with the protocol * Need for immediate psychiatric hospitalization * Enrolled in a medical marijuana program * Federal employee

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Neuropathic pain are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    4 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Providence VA Medical Center, Providence, RI

    RECRUITING

    Providence, Rhode Island, 02908-4734, United States

  • South Texas Health Care System, San Antonio, TX

    RECRUITING

    San Antonio, Texas, 78229-4404, United States

  • VA Connecticut Healthcare System West Haven Campus, West Haven, CT

    RECRUITING

    West Haven, Connecticut, 06516-2770, United States

  • VA Greater Los Angeles Healthcare System, West Los Angeles, CA

    ACTIVE_NOT_RECRUITING

    West Los Angeles, California, 90073-1003, United States

  • VA Puget Sound Health Care System Seattle Division, Seattle, WA

    TERMINATED

    Seattle, Washington, 98108-1532, United States

  • VA San Diego Healthcare System, San Diego, CA

    RECRUITING

    San Diego, California, 92161-0002, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.